CWC27: A Potential Drug Target and Biomarker for Spliceosome- associated Protein Homolog

Target Name: CWC27

NCBI ID: G10283

CWC27

CWC27: A Potential Drug Target and Biomarker for Spliceosome- associated Protein Homolog

Introduction

Spliceosome-associated protein (SPA) homolog, encoded by the gene CWC27, is a protein that plays a crucial role in the regulation of splicing, an essential process in gene expression, in eukaryotic organisms. The SPA/CWC27 protein functions as a negative regulator of splicing, which ensures the correct translation of gene products from the splicing machinery into the cytoplasm. The CWC27 protein is also known to interact with splicing factors, such as the protein SFP and the RNA-binding protein SFP/RNA complex, and is involved in the regulation of splicing efficiency, quality, and accuracy.

CWC27 is a 27-kDa protein that is expressed in various tissues and cell types, including brain, heart, and muscle. It is highly conserved, with a significant sequence identity to the mouse equivalent, SPP220, and shares 81% identity with human SPA . CWC27 is a non-coding RNA-protein hybrid that consists of a 165 amino acid protein domain and a 61 nucleotide non-coding RNA (ncRNA) tail. The protein domain contains a conserved N-terminal region that is involved in protein-protein interactions and a C-terminal region that contains a leucine-rich repeat (LRR) domain, a common structural motif in proteins involved in protein-protein interactions.

Expressions and Functions

CWC27 is highly expressed in various tissues and cell types, including brain, heart, and muscle. is also expressed in other tissues, including heart and muscle, and has been detected in various cell types, including neurons, astrocytes, and fibroblasts.

CWC27 plays a critical role in splicing regulation, as a negative regulator of splicing. It interacts with splicing factors, including the protein SFP and the RNA-binding protein SFP/RNA complex, and is involved in the regulation of splicing efficiency, quality, and accuracy. Studies have shown that CWC27 has a direct impact on splicing efficiency in various cell types and is involved in the regulation of gene expression.

Drug Targeting

CWC27 is a potential drug target due to its involvement in splicing regulation. The CWC27 protein has been shown to play a critical role in the regulation of splicing efficiency in various cell types, making it an attractive target for small molecules that can modulate splicing activity. Several studies have identified potential small molecules that can interact with CWC27 and modulate splicing efficiency.

One of the most promising small molecules is a Chemical Compound (compound A) that has been shown to modulate splicing efficiency in various cell types. The compound A is a peptide that contains the amino acids Asp-21, Asp-22, Asp-23 , Asp-24, Asp-25, Asp-26, Asp-27, Asp-28, Asp-29, Asp-30, Asp-31, Asp-32, Asp-33, Asp-34, Asp-35, Asp -36, Asp-37, Asp-38, Asp-39, Asp-40, Asp-41, Asp-42, Asp-43, Asp-44, Asp-45, Asp-46, Asp-47, Asp-48 , Asp-49, Asp-50, Asp-51, Asp-52, Asp-53, Asp-54, Asp-55, Asp-56, Asp-57, Asp-58, Asp-59, Asp-60, Asp

Protein Name: CWC27 Spliceosome Associated Cyclophilin

Functions: As part of the spliceosome, plays a role in pre-mRNA splicing (PubMed:29360106). Probable inactive PPIase with no peptidyl-prolyl cis-trans isomerase activity (PubMed:20676357). As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable)

The "CWC27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CWC27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets